Clinical trial
A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.
NCT01708993 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.
- Lead sponsor
- Canadian Cancer Trials Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 10, 2012
- Completion date
- September 26, 2018
- Enrollment
- 166 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
non small cell lung cancer